Momenta Phama (MNTA) Reports Q2 Loss Per Share of 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Goldman Sachs Downgrades Momenta Pharmaceuticals (MNTA) to Neutral
August 6, 2015 6:59 AM EDTGoldman Sachs downgraded Momenta Pharmaceuticals (NASDAQ: MNTA) from Buy to Neutral with a price target of $27 (unchanged).
For an analyst ratings summary and ratings history on Momenta Pharmaceuticals click here. For more ratings news on Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $23.12 yesterday.
... MoreCowen Raises Price Target on Momenta Phama (MNTA) Following 2Q Results
August 5, 2015 9:57 AM EDTCowen reiterated a Market Perform rating on Momenta Pharmaceuticals (NASDAQ: MNTA), and raised the price target to $23.00 (from $18.00), following 2Q results. MNTA reported 2Q EPS of ($0.04) vs consensus of ($0.19).
Analyst Ritu Baral commented, "Investor focus remains Glatopa sales. Early launch looks... More
Momenta Pharmaceuticals (MNTA) PT Raised to $26 at Leerink Partners
August 5, 2015 7:58 AM EDTLeerink Partners analyst Jason Gerberry bumped his price target on Outperform-rated Momenta Pharmaceuticals (NASDAQ: MNTA) to $26.00 (from $25.00) following Q2 results.
Gerberry commented, "... MNTA reported better-than-expected top-line revenue of ~$45m vs our est of ~$7m driven by better-than-expected revenue recognition from Glatopa... More
